Celltrion Accelerates Drive to Become a Global New Drug Company at BioUSA
Expanding Global Partnerships
with AI, ADCs, and Multispecific Antibodies at the Forefront
Celltrion announced on June 18 that it will participate in the 2026 Bio International Convention (Bio International Convention, also known as BioUSA), which will be held in San Diego, United States, from June 22 to 25, local time. The company aims to showcase its artificial intelligence (AI)-based new drug development capabilities and next-generation drug pipeline competitiveness to the global market, and to secure future growth engines by expanding global partnerships.
BioUSA is the world's largest bio-business event, where global big pharma companies, biotech firms, investment institutions, research organizations, and licensing experts gather to discuss joint research, technology transfers, investments, and strategic alliances. Marking its 33rd edition this year, the event is expected to attract more than 20,000 participants and visitors from over 1,500 pharmaceutical and biotech companies, investors, and research organizations worldwide.
Celltrion has participated in BioUSA for 17 consecutive years since 2010, continuously expanding its network with global pharmaceutical and biotech companies. This year, Celltrion will operate an independent booth spanning approximately 139 square meters, presenting its next-generation growth strategies and new drug development capabilities to the global market. The company also plans to conduct business meetings and technology exchanges with competitive firms.
In particular, Celltrion plans to use this year’s BioUSA not simply as a corporate promotional event, but as a global business platform to concretize its future growth strategies. Leveraging its accumulated R&D, manufacturing, and commercialization capabilities in the biosimilar sector, Celltrion intends to expand collaboration opportunities with global partners in next-generation technology areas such as AI-based drug development, antibody-drug conjugates (ADC), and multispecific antibodies.
At this year’s event, Celltrion will actively promote its AI-powered new drug development capabilities and business strategies. Taking advantage of its booth location within the AI Zone, Celltrion will introduce to global visitors the following: ▲ AI-based discovery of novel targets and portfolio expansion, ▲ AI-powered next-generation multispecific antibody design technology, ▲ in silico developability assessment technology, and ▲ a data-driven research platform (Healthcare Intelligence Bank).
Using AI, Celltrion is conducting research to design antibody candidates, evaluate their physicochemical properties, manufacturing suitability, and immunogenicity, and to predict and assess these factors. The company is also working to identify promising candidates with a high probability of clinical development success at early stages. Through these efforts, Celltrion aims to enhance the efficiency of the drug development process, shorten development timelines, and improve success rates. Additionally, the company is advancing a multimodal AI-based research platform that integrates and analyzes diverse research data, thereby further refining its data-driven drug development decision-making system.
Together with its AI-based research and development strategies, Celltrion will also focus on promoting its next-generation drug pipeline, including ADCs and multispecific antibodies, at this year’s event. The company is accelerating development in these areas to establish ADCs and multispecific antibodies as core future growth engines. Celltrion plans to actively present related technologies and pipeline progress to global pharmaceutical companies, biotech firms, and investors at the event.
Expanding global partnerships is also a key objective of Celltrion’s participation in BioUSA this year. During the event, Celltrion will hold numerous strategic meetings with global pharmaceutical companies and biotech firms to explore a variety of business opportunities, including licensing-in, joint development, and technology cooperation, aimed at expanding its biosimilar and new drug pipelines with strong marketability and competitiveness. The company also intends to strengthen its manufacturing and business competitiveness by meeting with materials, parts, and equipment suppliers to improve production efficiency and technology capabilities, as well as by discovering global partnerships that align with its core business areas.
A Celltrion representative stated, "BioUSA is the largest global business stage where bio companies, investors, and technology partners from around the world gather. Through this event, Celltrion plans to actively communicate its future business vision and technological competitiveness to the global market, as it strives to become a global new drug company beyond biosimilars."
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
The representative added, "By expanding global partnerships based on next-generation growth drivers such as the AI-based new drug development platform, ADCs, and multispecific antibodies, Celltrion will proactively seek out meaningful business opportunities that can contribute to the company’s mid- to long-term growth and increase corporate value."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.